# FDA recall D-0166-2025

> **MXBBB** · Class II · drug recall initiated 2024-11-14.

## Product

UMARY ACID HYALURONIC, 850 MG CAPLETS, 30-count bottle, UPC7502265120323

## Reason for recall

cGMP Deviations: the firm initiated a recall after notification from the distributor that product may be tainted with undeclared diclofenac and omeprazole, however there is no analytical data confirming that product distributed by the firm is tainted.

## Distribution

Product was sold via Amazon Marketplace.

## Key facts

- **Recall number:** D-0166-2025
- **Recalling firm:** MXBBB
- **Classification:** Class II
- **Product type:** drug
- **Status:** Ongoing
- **Initiation date:** 2024-11-14
- **Report date:** 2025-01-01

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** El Paso, TX, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0166-2025

## Citation

> AI Analytics. FDA recall D-0166-2025. Retrieved 2026-07-01 from https://api.ai-analytics.org/recall/D-0166-2025. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*